Germany

BMI View: While the AMNOG legislation will compress drug company's revenue-earning opportunities in Germany, we believe the country will remain an attractive location to launch drugs... 2012-06-20

BMI View: The drug markets of the EU5 countries, Germany, the UK, France, Spain and Italy, will experience a decline over the 2011-2016 forecast period. Our bearish outlook takes into... 2012-06-11

BMI view : Lipitor (atorvastatin)'s patent expiration brings significant revenue-earning opportunities for Ranbaxy Laboratories in Europe, particularly as cash-strapped governments... 2012-03-15

BMI View: Alhough Bayer improved its profitability in 2011, and continued to see moderate revenue growth, the real success of the year has been in its pharmaceutical pipeline with the... 2012-02-29

BMI View: Despite the threat of austerity measures and the government's focus on cost-containment within the pharmaceuticals and healthcare sector, as well as the impact of generic... 2012-01-18

BMI View: The importance of maintaining healthy research and development (R&D) pipelines and launching new drugs by innovative drugmakers cannot be stressed enough. The patent cliff... 2011-12-20

BMI View: In the short term, the halt in the delivery of drugs to German medicine wholesalers while Novartis negotiates discounts on drugs (fuelled by low interest rates and wholesalers'... 2011-12-02